These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 8226433)

  • 1. Efficacy of ceftriaxone plus tazobactam in a rat model of intraabdominal abscess due to Bacteroides fragilis.
    Pefanis A; Thauvin-Eliopoulos C; Eliopoulos GM; Moellering RC
    J Antimicrob Chemother; 1993 Aug; 32(2):307-12. PubMed ID: 8226433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of ceftriaxone combined with tazobactam against anaerobic bacteria.
    Wüst J; Hardegger U
    Eur J Clin Microbiol Infect Dis; 1994 Feb; 13(2):177-81. PubMed ID: 8013494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased in vitro activity of ceftriaxone by addition of tazobactam against clinical isolates of anaerobes.
    Aldridge KE; Morice N; Schiro DD
    Diagn Microbiol Infect Dis; 1994 Aug; 19(4):227-34. PubMed ID: 7851086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of rifampicin in experimental Bacteroides fragilis and Pseudomonas aeruginosa mixed infections.
    Fu KP; Lasinski ER; Zoganas HC; Kimble EF; Konopka EA
    J Antimicrob Chemother; 1985 May; 15(5):579-85. PubMed ID: 3924880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial activity of latamoxef (moxalactam) against both Bacteroides fragilis and Escherichia coli in an intraperitoneal abscess model.
    Harris RW; Moore WL; Arensman JB; Rissing JP
    J Antimicrob Chemother; 1984 Nov; 14(5):499-508. PubMed ID: 6392279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro susceptibility and in vivo efficacy of antimicrobials in the treatment of Bacteroides fragilis-Escherichia coli infection in mice.
    Brook I
    J Infect Dis; 1989 Oct; 160(4):651-6. PubMed ID: 2677161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of beta-lactam and inhibitor combinations in a diffusion chamber model in rabbits.
    Georgopoulos A; Buxbaum A; Graninger W
    J Antimicrob Chemother; 1999 Apr; 43(4):497-501. PubMed ID: 10350378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic efficacy and pharmacokinetic properties of rifampicin in a Bacteroides fragilis intra-abdominal abscess.
    Fu KP; Lasinski ER; Zoganas HC; Kimble EF; Konopka EA
    J Antimicrob Chemother; 1984 Dec; 14(6):633-40. PubMed ID: 6520063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of ceftriaxone plus tazobactam against members of Enterobacteriaceae.
    Prakash SK; Arora V; Prashad R; Sharma VK
    J Assoc Physicians India; 2005 Jul; 53():595-8. PubMed ID: 16190126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of fleroxacin alone and in combination with clindamycin or metronidazole in experimental intra-abdominal abscesses.
    Pefanis A; Thauvin-Eliopoulos C; Holden J; Eliopoulos GM; Ferraro MJ; Moellering RC
    Antimicrob Agents Chemother; 1994 Feb; 38(2):252-5. PubMed ID: 8192453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-vitro susceptibility and in-vivo efficacy of antimicrobials in the treatment of intraabdominal sepsis in mice.
    Brook I; Gillmore JD
    J Antimicrob Chemother; 1993 Mar; 31(3):393-401. PubMed ID: 8486573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Turbidimetric and microscopic analysis of Bacteroides fragilis exposed to tazobactam and piperacillin alone and in combination.
    Yourassowsky E; Van der Linden MP; Lismont MJ; Crokaert F
    Chemotherapy; 1990; 36(3):215-21. PubMed ID: 2159865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Vitro Activity of Ceftolozane-Tazobactam against Anaerobic Organisms Identified during the ASPECT-cIAI Study.
    Armstrong ES; Farrell DJ; Palchak M; Steenbergen JN
    Antimicrob Agents Chemother; 2016 Jan; 60(1):666-8. PubMed ID: 26552971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experimental intraabdominal abscess formation by Escherichia coli and bacteroides fragilis.
    Hagen JC; Wood WS; Hashimoto T
    Eur J Clin Microbiol; 1983 Feb; 2(1):43-9. PubMed ID: 6341050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial spectrum of cefpirome combined with tazobactam against the Bacteroides fragilis group.
    Jones RN; Croco JL; Barrett MS; Novick WJ; Erwin ME
    Diagn Microbiol Infect Dis; 1990; 13(5):371-3. PubMed ID: 2178078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo efficacy of trovafloxacin against Bacteroides fragilis in mixed infection with either Escherichia coli or a vancomycin-resistant strain of Enterococcus faecium in an established-abscess murine model.
    Stearne LE; Gyssens IC; Goessens WH; Mouton JW; Oyen WJ; van der Meer JW; Verbrugh HA
    Antimicrob Agents Chemother; 2001 May; 45(5):1394-401. PubMed ID: 11302801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Post antibiotic, post beta-lactamase inhibitor and post antibiotic sub-MIC effect of ceftriaxone/tazobactam on beta-lactamase-producing Escherichia coli in vitro].
    Zhang SC; Zhang LL; Chen SW; Wu HY; Liu XK
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Nov; 40(6):1071-4. PubMed ID: 20067122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In-vivo bactericidal activity of Sch 34343 in Bacteroides fragilis abscesses and in Bacteroides fragilis-Escherichia coli abscesses.
    Wells CL; Arland LA; Simmons RL; Rotstein OD
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():199-206. PubMed ID: 3897172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy of ceftriaxone in experimental infections involving Bacteroides fragilis and Escherichia coli.
    Dezfulian M; Bitar RA; Bartlett JG
    Chemotherapy; 1993; 39(5):355-60. PubMed ID: 8370326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibrin in peritonitis. IV. Synergistic intraperitoneal infection caused by Escherichia coli and Bacteroides fragilis within fibrin clots.
    Dunn DL; Rotstein OD; Simmons RL
    Arch Surg; 1984 Feb; 119(2):139-44. PubMed ID: 6365029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.